Efficacy Assessment of Insulin Glargine Versus LiraglutidE After Oral Agents Failure
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 978 participants.
Also called NCT01117350
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 978 participants
- Sponsor
- Registry
-
NCT01117350 -
2010-018437-21
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Austria, Brazil, Canada, Czechia, Finland, France, Greece, Ireland, Israel, Mexico, Netherlands, Russia, Slovakia, Spain, Sweden, Türkiye
- Registry status
- Completed
Technical summary
Registry record NCT01117350. Randomized; no masking; primary purpose treatment. Start 2010-07 (registry gives no type); primary completion 2012-10 (actual). Results posted on 2014-01-29.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy Assessment of Insulin Glargine Versus LiraglutidE After Oral Agents Failure
- Acronym
- EAGLE
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- Insulin glargine
- Intervention (Drug)
- Liraglutide
- Intervention (Drug)
- Metformin
- Lead sponsor
- Sanofi
Record details
- Record id
cardio:ct-nct01117350- Content hash
ce3943d1f849351dee0cda17cffacc16463ff8d47b5850f7b1965dd121bd1d83